A multi-clinic double-blind controlled study on amoxapine in comparison with imipramine. using the WHO Schedule for a Standard Assessment of Patients with Depressive Disorders. was performed and the data were analyzed with 111 patients.
Introduction
The clinical significance of antidepressive drugs in the treatment of depression is at present confirmed by clinical experience. However, there are still a considerable number of depressive patients who are refractory to the existing tricyclic antidepressants. In addition, most of the tricyclic drugs have a potent anticholinergic action, and it usual1y takes two to three weeks before the therapeutic responses take place. Therefore, the development of a new effective antidepressant with rapid onset of action as wel1 as less anticholinergic activity is particularly desirable from a clinical point of view.
Amoxapine is a new antidepressive agent, a dibenzoxazepine derivative analogous to loxapine. Since Gallant, Bishop and Guerrero-Figueroa (1971) reported its efficacy in the treatment of depression, the pilot studies and double-blind studies performed by Kellner et at (1972) , Charalampous (1972) , Ota, Turek and Kurland (1972) , Gallant et al (1973) , Sathanathan et at (1973) , Smith (1975) , Aberg and Holmberg (1977) have confirmed the efficacy of this substance. Also, in Japan, after the efficacy and safety were confirmed by animal studies (Saito et at 1971a , Saito et al 1971b and the Phase I test (Saito & Tojo 1976) , the clinical efficacy of amoxapine has been reported by many authors such as Hara, Murasaki and Yamazumi (1976) , Okamoto et at (1976) , and Hazama et al (1976) . These clinical trials have demonstrated that the antidepressive effect of amoxapine was equal or superior to other existing tricyclic antidepressants, the onset of its action was more rapid, and anticholinergic side-effects were infrequent and mild. On the basis of these findings, we designed and conducted a multiclinic double-blind controlled study to compare amoxapine with imipramine for the treatment of depressive patients.
In order to complete such a multi-clinic trial with success, the reliable agreement on the diagnosis as well as the evaluation of symptomatology of patients seems to be vitally essential. For this purpose, we tried to use the WHO Schedule for a Standard Assessment of Patients with Depressive Disorders, abbreviated as WHO-SADD. It was originally developed jointly by the international collaborative study of depression, and was employed in this study with the agreement of the WHO Headquarters.
In this paper, the antidepressive efficacy of amoxapine in comparison with that of imipramine will be reported. In addition, the usefulness of WHO-SADD for drug study will be also evaluated. Our study is the first to utilize this schedule for the evaluation of antidepressive drug efficacy.
Subjects and Methods
This study was performed according to a group comparison schema. The patient group treated with amoxapine was contrasted with the patient group treated with imipramine.
Subjects
Subjects of this trial consisted of 122 depressive patients who were either in-patients or out-patients of five university hospitals in Japan: Kitasato, Nagasaki, Toho, Tokyo and Teikyo University Hospitals. All of these patients had not been treated with other antidepressants or ECT for one week before this trial. Depressive states due to schizophrenia, organic brain syndrome or other somatic disease were excluded from the subjects.
Drugs
An amoxapine 25 mg capsule and an imipramine 25 mg capsule with identical appearance were used in this trial. A quantitative test and desolution test were performed on randomly taken drug samples prior to the trial and results confirmed the prescribed contents of the respective agents.
Medication schedule
Patients were assigned randomly to either the amoxapine or imipramine group. The initial daily dosage was determined for each patient according to the severity of illness. Namely, daily initial dosage of 50-75 mg for mild depression, 75-100 mg for moderate depression and 75-150 mg for severe depression. If there were neither improvement nor intolerable side-effects, the dosage was gradually increased as quickly as possible up to the daily maximum dose of 300 mg, twelve capsules. Drugs were administered three times a day, and the treatment period was from three to five weeks. Concomitant medications were forbidden except for mild hypnotics or several habitual drugs. Among the hypotensive drugs, the use of reserpine and a methyldopa was forbidden. Informed consent was obtained from each patient prior to the trial. 9 4 Assessment ofsymptoms In order to become familiar with WHO-SADD prior to starting drug administration, we spent six months practicing how to use it. All the participating twelve doctors got together ten times at regular intervals to master the accurate usage of this rating scale. Direct interviews with patients or audiotapes of psychiatric interviews were used for this purpose in the exercises. Medication was started after all the participating doctors were completely acquainted with this rating scale and had attained the level of high inter-rater reliability.
The efficacy of the drugs on each patient was assessed by the doctor in charge on a double-blind basis. The WHO-SADD consists of three parts: background data chart, list of a total of 37 symptoms and signs, and clinical diagnosis. The degree of all symptoms and signs was evaluated every week and classified into five categories: from 0 (no symptoms and signs) to 4 (extremely severe). The day when the first therapeutic response was recognized was also carefully recorded. For statistical handling, the 37 items of this schedule were regrouped into fourteen groups. The degree of severity of illness of each patient was evaluated every week and compared with the patient's untreated state. The results were classified into eight categories: from 1 (remarkable improvement) to 7 (very much worsening) and 8 (conversion to manic state). Final overall improvement was also assessed after the termination of medication.
Evaluation ofsafety and usefulness
The degree of side-effects and of accompanying symptoms was assessed at weekly intervals using a 4-point scale: from (0) normal to (3) remarkable. The following laboratory examinations were performed on each patient before medication and after Week 3 and Week 5 of treatment: urinalysis; complete blood cell count and differential; test of liver function and renal function; and electrocardiogram (ECG).
Considering the side-effects and results of clinical laboratory tests, the safety of the drug was assessed weekly and classified into five categories: (1) entirely safe, (2) continuous use possible, (3) need to decrease dose, (4) discontinuation (because of reversible side-effects) and (5) discontinuation (because of irreversible side-effects).
At the end of the trial, the usefulness of the drug as an antidepressant in each case was evaluated considering the overall improvement and safety, and classified into seven categories :
(1) very useful, (2) considerably useful, (3) fairly useful, (4) not useful, (5) fairly undesirable, (6) considerably undesirable and (7) very undesirable. These schedules can be expressed as follows: 6 Data analysis Prior to breaking the randomized code, all the data were fixed in the presence of all participants. After excluding eleven cases who had no available data or whose diagnoses were inappropriate, 111 patients were finally subjected to the statistical analysis. Relation between the severity and the background factors and that between the severity and symptoms, regrouped into 14 items, were examined according to the multiple regression analyses. For the comparison of the two drug groups, 2 sample t-test and 2 sample Wilcoxon test, if necessary, were applied to the metric data. For the data of ordered category, 2 sample Wilcoxon test, and for the data of categorical contingency table, routine chisquare test or Fisher's direct method were used respectively. In addition to these statistical tests, the estimations for the mean, median and rate were applied when necessary.
Further, we used the discriminant analysis, principal component analysis and other multivariate analyses to examine the detailed nature of the data. When the data were missing, the analyses were performed without such missing entries insofar as no problems were caused. If problems arose due to exclusion, re-examination was carried out each time. Upon assessing degree of improvement, two cases where the illness switched over to a
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Results

Composition ofthe two groups
By opening the randomized code, it was disclosed that fifty-four patients received amoxapine and fifty-seven patients received imipramine. There were no statistically significant differences between the two groups in terms of background factors. Table 1 and  Table 2 show demographic factors, family history, past history, concomitant medication and so on in the two groups, and Table 3 is the classification of the patients according to three different diagnostic classifications.
Changes in the severity ofillness
The data analysis on the severity of illness was mainly focused on the data of Weeks 1, 2 and .p = 0·069 (Fisher's direct method) AX: amoxapine IMP: imipramine > 1 year 9 3 AX: amoxapine IMP: imipramine 3, because early terminated cases increased during Weeks 4 and 5. A step-wise multiregression analysis revealed that the following symptoms were reflecting well the severity of depression: depressive feeling, psychomotor retardation, ideas of depreciated self-image, irritability and excitation, somatic symptoms, and pains and other somatic symptoms. By comparing the weekly general assessment of severity between the two drugs, a clear difference was found at Weeks 1 and 2 (p = 0·019 and p = 0·0004 respectively), although there were no differences at Week 0, Week 3, Week 4, and Week 5. At Week 2, the degree of severity of illness in the amoxapine group became less severe than that in the imipramine group. Namely, there was a one-step difference between the median value of severity in the two groups.
11
3 Overall improvement The degree of improvement in the amoxapine group was superior to that of the imipramine group at Week 1 (p = 0·011). This difference became more evident at Week 2 (p = 0·0002).
After Week 3, this difference became unclear. Figure 1 shows the accumulative curves of improvement at Week 2. These curves clearly demonstrate that improvement was obtained in 81· 1% of the amoxapine group at Week 2, and in only 66·0% of the imipramine group. Table 4 shows the improvement rate in both groups according to diagnostic classifications.
It also demonstrates that amoxapine was superior to imipramine for all types of depression, although it was not shown to be effective for any specific sub-types. The difference of improvement rate between both groups seen at Week 1 and Week 2 seems to indicate the more immediate antidepressive action of amoxapine. Namely, the immediate clinical effect was obtained in 64·8% of the amoxapine group, while it was obtained in only 36·8% of the imipramine group. The median value of number of days where the onset of antidepressive action was noted in the amoxapine group was four days, and in the imipramine group eight days. Table 5 shows the general assessment of safety at Weeks 1, 2 and 3. The safety in the amoxapine group was always superior to that in the imipramine group (p = 0·002, P = 0·002, P = 0·143). Especially at Week 2, the decrease of posology and the number of terminated cases due to side-effects were more remarkable in the imipramine group. Table 6 illustrates the incidence of common side-effects in both groups. Vertigo and dizziness, dry mouth, tachycardia, and constipation were almost equally seen in both groups. However, perspiration, hypotension, nausea and vomiting, and precordial pain were more frequently seen in the imipramine group. The two cases in which the drug administration was discontinued because of severe side-effects belonged to the imipramine group.
Safety and side-effects
Usefulness
The usefulness of the drugs was evaluated at Weeks 3, 4 and 5. This result is shown in Table 7 . Analyzing the results as data in the ordinal scale, the usefulness at the end of Week 3 was obviously greater in the amoxapine group than in the imipramine group (p = 0·006). The usefulness including more than 'fairly useful' was 80·8% in the amoxapine group and 60· 7% in the imipramine group. This difference was statistically significant at the 5% level.
Comparison of clinical effects of each symptom and sign
The comparison of the degree of symptoms and signs by t-test prior to the trial revealed no difference between the two groups. Then the difference between the severity of symptoms and signs at Week 0 and that at the week internal was compared between the two groups. As shown in Figure 2 , the improvement of psychomotor retardation was found more clearly in the amoxapine group at Week 1, and the improvement of depressive feeling, anxiety and tension, psychomotor retardation, somatic complaints and sleep disturbance was also seen more remarkably in the amoxapine group at Week 2.
Of the symptoms which presented remarkable changes at Week 2, psychomotor retardation showed the most remarkable improvement in the amoxapine group. The discriminant analysis to all symptom items demonstrated that improvement of several symptoms such as anxiety and tension, psychomotor retardation, somatic complaints and sleep disturbance was more remarkable in the amoxapine group than in the imipramine group at Week 2. At Week 3, there was little difference in the improvement of symptoms between the two groups. It was felt that the superiority of amoxapine to imipramine in its efficacy was most obviously observed at Week 2, and it seems to reflect the earlier onset of therapeutic effect in the amoxapine group.
7 Laboratory findings There were no differences in terms of incidence of abnormal laboratory finding, including ECG, in both groups. Abnormal laboratory data indicating any serious dysfunction of internal organs were not observed during the trial.
Drop-out or early terminated cases
In twenty patients of the amoxapine group and twenty-eight patients of the imipramine group, the drug administration was terminated before the end of the fifth week. As shown in Table 8 , ten out of a total of twenty cases in the amoxapine group discontinued medication because of early favourable response, while in the imipramine group, twenty-six out of twenty-eight cases discontinued medication because of no response, worsening or sideeffects.
Discussion
In this double-blind trial, the improvement rate of depressive patients in the amoxapine group was 86 ·0%, and in the imipramine group it was 64·9%. These figures are similar to the results obtained in several double-blind studies so far reported in other countries (Sathananthan et al1973, Gallant et aI1973) .
The results obtained in this study strongly suggest the superiority of amoxapine to imipramine in its antidepressive action, rapid onset of therapeutic action, and clinical safety. In the past, there were a number of antidepressive agents introduced on the market with the catch-phrase 'immediate efficacy'. However, no drug had an immediate effect comparable to amoxapine in this study. Asterisk and square in parenthesis indicate comparison of differences from Week abetween the two drug groups . According to many clinical studies so far reported, amoxapine is said to have weak anticholinergic activity, and the incidence of side-effects is very low. In this study too, the safety of amoxapine as well as the low incidence of its side-effects was obviously confirmed. With regard to the data obtained by evaluating the effect of amoxapine on each symptom and sign of depression, this drug exerted specifically an excellent effect on psychomotor retardation, depressive feeling, anxiety and tension, somatic complaints and sleep disturbance. These characteristics coincide well with the findings reported in the double-blind studies by using the Hamilton Rating Scale for Depression (Chalampous 1972 , Smith 1975 . Considering both safety and overall improvement rate, the usefulness of amoxapine in the treatment of depression seems to be superior to that of imipramine.
In our study, amoxapine was effective in alleviating anxiety and tension seen in depressive patients. This positive finding could shed some light on the anti-anxiety action of amoxapine which has been so far disputed by many investigators (Hara et al 1976 , Kirikae 1976 , Okamoto et a11976, Mori et al 1976 .
Finally, the usefulness of the WHO Schedule for a Standard Assessment of Patients with Depressive Disorders in the drug study deserves brief mention here. Although this schedule was originalIy designed for the international standardization of assessment of symptoms and signs of depression and not for the rating of drug efficacy, our study has proved that this schedule was also very useful in the drug study if the participating psychiatrists are thoroughly acquainted with it. Therefore, we believe that this schedule can provide internationalIy standard useful criteria for the clinical evaluation of new antidepressive agents.
Conclusion
1 The antidepressive efficacy of amoxapine was clearly demonstrated to be superior to that of imipramine in a multi-clinic doubleblind controlIed study using the WHO Schedule for a Standard Assessment of Patients with Depressive Disorders. 2 The characteristic features of amoxapine were more rapid onset of action and less frequent side-effects in comparison with imipramine. 3 The effect of amoxapine is specifically prominent on such symptoms as psychomotor retardation, depressive feeling, anxiety and tension, somatic complaints and sleep disturbance. 4 The usefulness of the WHO Schedule for a Standard Assessment of Patients with Depressive Disorders for the clinical evaluation of antidepressive drugs was also proved in this study.
